Pedro J Prada1, Juan Cardenal2, Ana García Blanco2, Javier Anchuelo2, María Ferri2, Gema Fernández3, Elisabeth Arrojo3, Andrés Vázquez4, Maite Pacheco4, José Fernández5. 1. Department of Radiation Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain. Electronic address: pprada@telecable.es. 2. Department of Radiation Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain. 3. Department of Radiation Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain. 4. Department of Radiation Physics, Hospital Universitario Marqués de Valdecilla, Santander, Spain. 5. Department of Radiation Physics, Hospital Universitario Central de Asturias, Oviedo, Spain.
Abstract
BACKGROUND: To evaluate acute and late genitourinary, the gastrointestinal toxicity and the long-term biochemical control after HDR monotherapy in one fraction (19Gy). PATIENTS AND METHODS: Between April 2008 and October 2010, 60 consecutive patients were treated with favorable clinically localized prostate cancer; the median follow-up was 72months (range 32-91). All patients received one implant and one fraction of HDR. Fraction dose was 19Gy. Toxicity was reported according to the Common Toxicity Criteria for Adverse Event, Version 4.0 (CTAE v4.02) by the National Cancer Institute. RESULTS: No intraoperative or perioperative complications occurred. Acute toxicity grade 2 or more was not observed in any patients. No chronic toxicity, such as incontinence, late urinary retention, urethral narrowing, rectal bleeding, anal ulcer and/or rectourethral fistula has been observed after treatment. The overall survival and failure in tumor-free survival (TFS) according to Kaplan-Meier estimates was 90% (±5%) and 88% (±5%) respectively at 6years. The actuarial biochemical control was 66% (±6%) at 6years. CONCLUSIONS: This protocol is feasible and very well tolerated with low genitourinary morbidity, no gastrointestinal toxicity but no the same level of LDR biochemical control at 6years.
BACKGROUND: To evaluate acute and late genitourinary, the gastrointestinal toxicity and the long-term biochemical control after HDR monotherapy in one fraction (19Gy). PATIENTS AND METHODS: Between April 2008 and October 2010, 60 consecutive patients were treated with favorable clinically localized prostate cancer; the median follow-up was 72months (range 32-91). All patients received one implant and one fraction of HDR. Fraction dose was 19Gy. Toxicity was reported according to the Common Toxicity Criteria for Adverse Event, Version 4.0 (CTAE v4.02) by the National Cancer Institute. RESULTS: No intraoperative or perioperative complications occurred. Acute toxicity grade 2 or more was not observed in any patients. No chronic toxicity, such as incontinence, late urinary retention, urethral narrowing, rectal bleeding, anal ulcer and/or rectourethral fistula has been observed after treatment. The overall survival and failure in tumor-free survival (TFS) according to Kaplan-Meier estimates was 90% (±5%) and 88% (±5%) respectively at 6years. The actuarial biochemical control was 66% (±6%) at 6years. CONCLUSIONS: This protocol is feasible and very well tolerated with low genitourinary morbidity, no gastrointestinal toxicity but no the same level of LDR biochemical control at 6years.
Authors: Quentin Adams; Karolyn M Hopfensperger; Yusung Kim; Xiaodong Wu; Weiyu Xu; Hemant Shukla; James McGee; Joseph M Caster; Ryan T Flynn Journal: Int J Radiat Oncol Biol Phys Date: 2018-08-06 Impact factor: 7.038
Authors: Marko Rak; Tim König; Klaus D Tönnies; Mathias Walke; Jens Ricke; Christian Wybranski Journal: Int J Comput Assist Radiol Surg Date: 2017-07-06 Impact factor: 2.924
Authors: Esther Mayrata; Jose Maria Espinosa; David Büchser; Francisco Casquero; Fernan Suárez; Alba González; Pablo Minguez; Jose Fernando Pérez; Iñigo San Miguel; Jon Cacicedo; Alfonso Gómez-Iturriaga Journal: J Contemp Brachytherapy Date: 2021-02-18
Authors: Metha Maenhout; Max Peters; Marco van Vulpen; Marinus A Moerland; Richard P Meijer; Maurice A A J van den Bosch; Paul L Nguyen; Steven J Frank; Jochem R N van der Voort van Zyp Journal: Technol Cancer Res Treat Date: 2017-12-05
Authors: Damián Guirado; Samuel Ruiz-Arrebola; Ana M Tornero-López; Jose M de la Vega; Pedro J Prada; Antonio M Lallena Journal: J Contemp Brachytherapy Date: 2020-04-18